StockDrifts LogoStockDrifts

central vaccine 072020

Company
중앙백신central vaccine
Insiders
4
Buys
8
Total Value
₩465M ($323K)
Avg Return
-9.74%
Last Filing
2026-06-10

central vaccine (072020) has 8 disclosed insider purchases and 1 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩465M ($323K) in reported transaction value. The earliest filing StockDrifts holds for central vaccine is dated 2021-05-31; the most recent is 2026-06-10. Across these filings the average return since disclosure is -9.74%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-01BUYMarket Buy
신영학
Younghak Shin
moving2.2K₩9,200+1.0%₩20M ($14K)
2026-06-10BUYMarket Buy
윤인중
Yoon In-joong
CEO11.0K---
2026-04-28BUYMarket Buy
김은희
Eunhee Kim
Managing Director6.2K₩9,870+2.7%₩61M ($42K)
2026-04-27BUYMarket Buy
김은희
Eunhee Kim
Managing Director24.8K₩9,810+3.4%₩244M ($169K)
2026-04-27BUYMarket Buy
윤석인
Seokin Yoon
Each CEO3.3K₩9,810+3.4%₩32M ($22K)
2026-04-24BUYMarket Buy
윤석인
Seokin Yoon
Each CEO10.3K₩9,830+3.1%₩101M ($70K)
2025-01-01BUY신규선임
윤석인
Seokin Yoon
moving717.2K₩9,850-1.0%₩7.1B ($4.9M)
2024-11-01SELLMarket Sell
최환원
Choi Hwan-won
Managing Director-2.6K₩10,590+7.9%₩27M ($19K)
2022-09-23BUYMarket Buy
최환원
Choi Hwan-won
Managing Director1₩11,550-15.6%₩12K ($8)
2021-08-19BUYMarket Buy
최환원
Choi Hwan-won
Managing Director2₩15,750-38.1%₩32K ($22)
2021-05-31BUYMarket Buy
최환원
Choi Hwan-won
Managing Director2₩17,650-44.8%₩35K ($25)

Frequently asked questions

Who has been buying central vaccine stock?
4 distinct insiders have filed 8 disclosed insider purchases in central vaccine (072020), most recently on 2026-06-10. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does central vaccine have?
central vaccine has 8 buy-side and 1 sell-side disclosures on record, covering ₩465M ($323K) in total reported value, spanning 2021-05-31 to 2026-06-10.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.